Advance Publication Cover Page



# Facile Construction of an α-(1-Cyclopentenyl)ketone Core by Ruthenium-Catalyzed Hydrative Cyclization of 1,6-Allenyne: Total Synthesis of (+)-Myomontanone

Koichi Katagiri, Haruka Kodera, Masanori Tayu, and Nozomi Saito\*

Advance Publication on the web May 28, 2019 doi:10.1246/cl.190202

© 2019 The Chemical Society of Japan

Advance Publication is a service for online publication of manuscripts prior to releasing fully edited, printed versions. Entire manuscripts and a portion of the graphical abstract can be released on the web as soon as the submission is accepted. Note that the Chemical Society of Japan bears no responsibility for issues resulting from the use of information taken from unedited, Advance Publication manuscripts.

## Facile Construction of an α-(1-Cyclopentenyl)ketone Core by Ruthenium-Catalyzed Hydrative Cyclization of 1,6-Allenyne: Total Synthesis of (+)-Myomontanone

Koichi Katagiri, Haruka Kodera, Masanori Tayu and Nozomi Saito\* Meiji Pharmaceutical University, Kiyose, Tokyo 204-8588, Japan

E-mail: nozomi-s@my-pharm.ac.jp

40

48

49


50 51

65

1 2 Ruthenium-catalyzed hydrative cyclization of 1,6allenyne in the presence of  $H_2O$  was demonstrated. The reaction proceeded via nucleophilic attack of  $H_2O$  to a 3 4 giving ruthenacyclopentene intermediate, an  $\alpha$ -(1cyclopentenyl)ketone derivative under mild conditions. In 5 6 addition, the total synthesis of (+)-myomontanone was using ruthenium-catalyzed achieved by hydrative 8 cyclization of 1,6-allenye as a key step.

9 Keywords: 1,6-Allenyne,  $\alpha$ -(1-cyclopentenyl)ketone, 10 ruthenium

11 An  $\alpha$ -(1-cyclopentenyl)ketone core is a key structure 12 found in a number of biologically active natural products such as alterbrasone (Figure 1, 1),<sup>1</sup> eucalmaidial A  $(2)^2$  and 13 16-dehydropregnenolone (16-DHP, 3).<sup>3</sup> Moreover,  $\alpha$ -(1-14 15 cyclopentenyl)ketone derivatives have been recognized as 16 useful building blocks for the synthesis of complex organic 17 molecules.4 Therefore, various methodologies for 18 construction of the  $\alpha$ -(1-cyclopentenyl)ketone core such as 19 an intramolecular aldol condensation,5a [3+2] cycloaddition,<sup>5b</sup> intramolecular Rauhut-Currier reaction<sup>5c</sup> 20 and Morita-Baylis-Hillman reaction<sup>5d</sup> have been developed. 21 22




23 24 25

Figure 1. Representative bioactive molecules including an  $\alpha$ -(1cyclopentenyl)ketone core.


26 We previously reported regio- and stereoselective 27 synthesis of 1,2-bisalkylidenecyclopentane derivatives 5 by 28 ruthenium-catalyzed cyclization of 1,6-allenynes 4 via 29 addition of nucleophiles to ruthenacyclopentenes (Scheme 30  $1).^{6}$ Thus, the reaction proceeded via formation of 31 ruthenacycle I generated by oxidative cyclization of 4 to the 32 ruthenium complex, from which protonation occurred at the 33  $\gamma$ -position of I, to give the ruthenium carbene intermediate 34 II. Finally, addition of nucleophile (Nu-H) to the ruthenacycle II followed by reductive elimination from 35

36 intermediate III resulted in production of the 1,2-37 bisalkylidenecyclopentane derivative 5.



**Scheme 1.** Cyclization of 1,6-allenye via addition of nucleophile to ruthenacyclopentene.


41 Based on the above background, we planned 42 ruthenium-catalyzed cyclization of 1,6-allenyne in the 43 presence of H<sub>2</sub>O (Scheme 2). If the reaction of 1,6-allenyne 44 **4** would proceed via addition of less nucleophilic H<sub>2</sub>O,  $\alpha$ -45 (1-cyclopentenyl)ketone derivative **7** could be obtained by 46 tautomerization from dinenyl alcohol **6** under mild 47 conditions.<sup>7</sup>



Scheme 2. Strategy for the construction of  $\alpha$ -(1cyclopentenyl)ketone by cyclization of 1,6-allenyne accompanied by addition of H<sub>2</sub>O.

52 To examine the feasibility of the above plan, we first 53 investigated reaction conditions (Table 1). 1,6-Allenyne 4a 54 was reacted with 10 equivalents of H<sub>2</sub>O in the presence of 55 10 mol% of Cp\*RuCl(cod) in THF at room temperature, 56 giving 7a in only 8% yield (run 1). When a 57 [Cp\*Ru(MeCN)<sub>3</sub>]PF<sub>6</sub> catalyst was used instead of 58 Cp\*RuCl(cod), 4a was consumed within 2 hours, and 7a 59 was obtained in 74% yield (run 2). After investigation of 60 the effects of quantity of H<sub>2</sub>O on the yield of 7a (runs 2-5), we found that hydrative cyclization of 4a in the mixed 61 62 solvent of THF and H<sub>2</sub>O in a ratio of 10 to 1 proceeded 63 smoothly to give 7a in high yield (run 5). 64

Table 1. Optimization of reaction conditions.



<sup>*a*</sup> Allenyne **4a** was recovered in 74% yield.

<sup>b</sup> The reaction was carried out in a mixed solvent of THF and  $H_2O(v/v = 10/1)$ .


With the optimal conditions in hand, we explored the 6 7 substrate scope of the hydrative cyclization (Table 2). First, the structure of the linker part between allene and the alkyne 8 moiety was investigated (runs 1-3). As a result, the reaction 9 10 conditions were tolerated by not only 1,6-allenynes having 11 an ester moiety 4b and hydroxyl group 4c but also those 12 having acid-labile acetonide moiety 4d, and the corresponding cyclized products 7b-d were obtained in high 13 yields. The reaction of a substrate bearing an isopropyl 14 15 group on the allene part 4e gave the cyclopentenylketone 16 derivative 7e in 68% yield (run 4). On the other hand, the 17 reaction of allenyne having a terminal allene moiety 4f gave 18 no desired cyclized product 7f (run 5). Finally, the effect of 19 substituents on the alkyne part was examined (runs 6-10). 20 As a result, it was found that various 1,6-allenyenes having 21 aromatic groups or oxygen functionalities including an acid-22 labile siloxy or acetal moiety (4g-k) were applicable to the 23 corresponding reaction conditions, and the 24 cyclopentenylketone derivatives 7g-k were obtained in good 25 to high yields.

2

3


4

5



<sup>b</sup> The reaction was carried out at 50 °C.

31 Next, we turned our attention to the application of 32 hydrative cyclization to total synthesis of 33 furanosesquiterpene, (+)-myomontanone (Figure 2, 8).8 34 Myomontanone (8) is a major component that accounts for 35 70% of the essential oil contained in Myoporumu montanum, 36 which belongs to the Myoporaceae family originating in 37 Western Australia. In 1983, Sutherland's group isolated and determined the structure of 8.8a Although Dinsdale and co-38 39 workers reported that a metabolic active substance of 8 40 caused lung injury and liver damage,8b the biological 41 activity of 8 itself has not been determined. On the other hand, the only example of total synthesis 8 was 42 43 demonstrated by Roussis' group.9 In this context, we 44 envisaged that if the above hydrative cyclization was 45 applicable to the allenyne 9 having a 3-furyl group on the 46 alkyne part, total synthesis of 8 could be achieved. 47



48

49

61 62

63

27


28

29

30

Figure 2. Structure of (+)-myomontanone (8).

50 Synthesis of allenyne 9 is shown in Scheme 3. Asymmetric Evans alkylation<sup>10,11</sup> of **10** with literature-51 known propargyl bromide 1112 provided 12 in 70% yield in 52 53 a highly diastereoselective manner. Reductive removal of 54 the oxazolidinone part from 12 followed by oxidation and 55 alkylation with 13 generated from 3-methylbut-1-yne and 56 "BuLi gave divne derivative 14. Finally, allenvne 9 was 57 obtained by deoxygenation<sup>13</sup> of 14 by treatment of o-58 nitrobenzenesulfonylhydrazide (NBSH) under Mitsunobu 59 conditions. 60




Scheme 3. Synthesis of allenyne 9 via asymmetric Evans alkylation

### Table 2. Hydrative cyclization of vatious1,6-allenynes.<sup>a</sup>

run	substrate	time	yield
	4	(h)	(%)
	/=/ <sup>/</sup> Bu		x I <sup>7</sup> Bu O
	×		T T
1	$4\mathbf{b} \left[ \mathbf{X} = \mathbf{C} (\mathbf{CO}_2 \mathbf{M} \mathbf{e})_2 \right]$	2	<b>7b</b> : 84%
2	$4c [X = C(CH_2OH)_2]$	16	7c: 97%
3	$4d\left(X=\underbrace{\bigvee}_{O}\overset{V}{\underset{J,J'}{\overset{V}}}\right)$	16	7 <b>d</b> : 94%
	$\begin{array}{c} & \\ MeO_2C \\ MeO_2C \\ \end{array} \xrightarrow{R^2} \\ \end{array}$		MeO <sub>2</sub> C MeO <sub>2</sub> C MeO <sub>2</sub> C
4	4e ( $R^1 = {}^{i}Pr, R_2 = H$ )	16	7e: 68%
5	$4f(R^1 = R^2 = H)$	16	7f: -
	MeO <sub>2</sub> C		MeO <sub>2</sub> C MeO <sub>2</sub> C
	MeO <sub>2</sub> C´ \R <sup>3</sup>		R <sup>3</sup>
6	$4g(R^3 = C_6H_5)$	16	7g: 89%
7	<b>4h</b> ( $R^3 = CH_2OH$ )	19	7h: 96%
8	$4\mathbf{i} (\mathbf{R}^3 = \mathbf{CH}_2 \mathbf{OTBS})$	19	7i: 63%
9	$4\mathbf{j} (\mathbf{R}^3 = \mathbf{CH}_2\mathbf{OAc})$	16	7 <b>j</b> : 64%

2

Ruthenium-catalyzed hydrative cyclization of 9 1 2 proceeded smoothly to give (+)-myomontanone (8), for which spectral data including the value of optical rotation 3 4 were identical to those reported previously, in good yield 5 (Scheme 4).8



8 Scheme 4. Synthesis of (+)-myomontanone (8)

9 In summary, we succeeded in the development of a 10 synthetic methodology of  $\alpha$ -(1-cyclopentenyl)ketone 11 derivatives by ruthenium-catalyzed hydrative cyclization of 12 1,6-allenyne. Furthermore, concise total synthesis of (+)-13 myomontanone by the above hydrative cyclization was 14 demonstrated. Further studies along this line are in progress. 15

### **Supporting Information** 16

17 Electronic Supplementary Information (ESI) available: 18 experimental procedures and characterization data, including <sup>1</sup>H and <sup>13</sup>C NMR spectra for new compounds. 19 20 Supporting Information available is on 21 http://dx.doi.org/10.1246/cl.\*\*\*\*\*.

#### 22 **References and Notes**

- L. H. Zhang, H. W. Wang, J. Y. Xu, J. Li, L. Liu, Nat. Prod. Res. 1 2016, 30, 2305.
- 2 L.-W. Tian, M. Xu, X.-C. Li, C.-R. Yang, H.-J. Zhu, Y.-J. Zhang, RSC Adv. 2014, 4, 21373
- 3 a) J.-Å. Gustafsson, C. H. L. Shackleton, J. Sjövall, Eur. J. Biochem. 1969, 10, 302 b) J. Wu, C. Xia, J. Meier, S. Li, X. Hu, D. S. Lala, Mol. Endocrinol. 2002, 16, 1590.
- 2342267890333333678904142344567890152535 4 For selected recent examples, see: a) A. Y. Hong, M. R. Krout, T. Jensen, N. B. Bennett, A. M. Harned, B. M. Stoltz, Angew. Chem. Int. Ed. 2011, 50, 2756. b) A. V. Silva-Ortiz, E. Bratoeff, T. Ramírez-Apan, Y. Heuze, A. Sánchez, J. Soriano, M. Cabeza, Bioorg. Med. Chem. 2015, 23, 7535. c) J. D. Vasta, A. Choudhary, K. H. Jensen, N. A. McGrath, R. T. Raines, Biochemistry, 2017, 56, 219. d) Y. Chen, W. Zhang, L. Ren, J. Li, A. Li, Angew. Chem. Int. Ed. 2018, 57, 952. e) N. S. Nadaraia, N. N. Barbakadze, M. L. Kakhabrishvili, B. Sylla, A. Pichette, U. S. Makhmudov, Chem. Nat. Compd. 2018, 54, 310. f) D. C. Duquette, T. Jensen, B. M. Stoltz, J. Antibiot. 2018, 71, 263.
- 5 For selected recent examples, see: a) A. Y. Hong, M. R. Krout, T. Jensen, N. B. Bennett, A. M. Harned, B. M. Stoltz, Angew. Chem. Int. Ed. 2011, 50, 2756. b) Q. Zhao, X. Han, Y. Wei, M. Shi, Y. Lu, Chem. Commun. 2012, 48, 970. c) X.-N. Zhang, M. Shi, Eur. J. Org. Chem. 2012, 6271. d) C. Peter, P. Geoffroy, M. Miesch, Org. Biomol. Chem. 2018, 16, 1381.
- 6 N. Saito, Y. Kohyama, Y. Tanaka, Y. Sato, Chem. Commun. 2012, 48, 3754.
- For precedent examples of cyclization reactions via addition of H<sub>2</sub>O to ruthenacycle, see: a) B. M. Trost, M. T. Rudd, J. Am. Chem. Soc. 2003, 125, 11516. b) B. M. Trost, M. T. Rudd, Org. Lett. 2003, 5, 4599. c) B. M. Trost, X. Huang, Org. Lett. 2005, 7, 2097. d) B. M. Trost, X. Huang, Chem. Asian J., 2006, 1, 469. e) M. Zhang, H.-F. Jiang, H. Neumann, M. Beller, P. H. Dixneuf,

Angew. Chem. Int. Ed. 2009, 48, 1681. f) M. Zhang, H. Jiang, P. H. Dixneuf, Adv. Synth. Catal. 2009, 351, 1488. g) Y. Yamamoto, K. Yamashita, H. Nishiyama, Chem. Commun. 2011, 47, 1556.

- 8 a) P. L. Métra, M. D. Sutherland, Tetrahedron Lett. 1983, 24,
- 1749. b) J Hrdlicka, D. Dinsdale, A. A. Seawright, Int. J. Exp. Path. 1990, 71, 441.
- 9 V. Roussis, T. D. Hubert, Liebigs Ann. Chem. 1992, 539.
- 10 For the general asymmetric alkylation procedure, see: D. A. Evans, M. D. Ennis, D. J. Mathre, J. Am. Chem. Soc. 1982, 104, 1737
- 11 For an asymmetric Evans alkylation with a propargylic bromide, see: M. Savignac, J.-O. Durand, J.-P. Genêt, Tetrahedron: Asymmetry 1994, 5, 717.
- 12 C. F. Ingham, R. A. Massy-Westropp, G. D Reynolds, Aust. J. Chem. 1974, 27, 1477.
- 66 67 68 69 70 71 13 A. G. Myers, M. Movassaghi, B. Zheng, J. Am. Chem. Soc. 1997, 119.8572.

6

7